Blocking the B7-H4 pathway with novel recombinant antibodies enhances T cell-mediated antitumor responses

B7-H4 inhibits T-cell activation and is widely expressed by solid neoplasms. We have recently demonstrated that the expression of B7-H4 on the surface of malignant cells in vivo is inducible, and that novel anti-B7-H4 recombinant antibodies can reverse the inhibition of tumor-specific T cells. Thus,...

Descripción completa

Detalles Bibliográficos
Autores principales: Dangaj, Denarda, Scholler, Nathalie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Point of View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782523/
https://www.ncbi.nlm.nih.gov/pubmed/24083083
http://dx.doi.org/10.4161/onci.25913
_version_ 1782285569424883712
author Dangaj, Denarda
Scholler, Nathalie
author_facet Dangaj, Denarda
Scholler, Nathalie
author_sort Dangaj, Denarda
collection PubMed
description B7-H4 inhibits T-cell activation and is widely expressed by solid neoplasms. We have recently demonstrated that the expression of B7-H4 on the surface of malignant cells in vivo is inducible, and that novel anti-B7-H4 recombinant antibodies can reverse the inhibition of tumor-specific T cells. Thus, antibodies targeting the B7-H4 pathways may extend the survival of cancer patients by restoring T cell-mediated antitumor responses.
format Online
Article
Text
id pubmed-3782523
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-37825232013-09-30 Blocking the B7-H4 pathway with novel recombinant antibodies enhances T cell-mediated antitumor responses Dangaj, Denarda Scholler, Nathalie Oncoimmunology Point of View B7-H4 inhibits T-cell activation and is widely expressed by solid neoplasms. We have recently demonstrated that the expression of B7-H4 on the surface of malignant cells in vivo is inducible, and that novel anti-B7-H4 recombinant antibodies can reverse the inhibition of tumor-specific T cells. Thus, antibodies targeting the B7-H4 pathways may extend the survival of cancer patients by restoring T cell-mediated antitumor responses. Landes Bioscience 2013-08-01 2013-07-31 /pmc/articles/PMC3782523/ /pubmed/24083083 http://dx.doi.org/10.4161/onci.25913 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Point of View
Dangaj, Denarda
Scholler, Nathalie
Blocking the B7-H4 pathway with novel recombinant antibodies enhances T cell-mediated antitumor responses
title Blocking the B7-H4 pathway with novel recombinant antibodies enhances T cell-mediated antitumor responses
title_full Blocking the B7-H4 pathway with novel recombinant antibodies enhances T cell-mediated antitumor responses
title_fullStr Blocking the B7-H4 pathway with novel recombinant antibodies enhances T cell-mediated antitumor responses
title_full_unstemmed Blocking the B7-H4 pathway with novel recombinant antibodies enhances T cell-mediated antitumor responses
title_short Blocking the B7-H4 pathway with novel recombinant antibodies enhances T cell-mediated antitumor responses
title_sort blocking the b7-h4 pathway with novel recombinant antibodies enhances t cell-mediated antitumor responses
topic Point of View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782523/
https://www.ncbi.nlm.nih.gov/pubmed/24083083
http://dx.doi.org/10.4161/onci.25913
work_keys_str_mv AT dangajdenarda blockingtheb7h4pathwaywithnovelrecombinantantibodiesenhancestcellmediatedantitumorresponses
AT schollernathalie blockingtheb7h4pathwaywithnovelrecombinantantibodiesenhancestcellmediatedantitumorresponses

Ejemplares similares